The microfibril hypothesis of glaucoma: Implications for treatment of elevated intraocular pressure

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 2-3, 2014, Pages 170-180

  Kuchtey, John ^a   Kuchtey, Rachel W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; AZILSARTAN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCIUM ION; CANDESARTAN; DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE; ELASTIN; EPROSARTAN; FIBRILLIN 1; FIBRONECTIN; FIBULIN; GROWTH DIFFERENTIATION FACTOR 5; IRBESARTAN; LOSARTAN; MYOSTATIN; OLMESARTAN; OSTEOGENIC PROTEIN 1; TELMISARTAN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN; VERSICAN; VITRONECTIN;

AQUEOUS HUMOR; BASEMENT MEMBRANE; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; COMPLEX FORMATION; CUTIS LAXA; ECTOPIA LENTIS; ELASTIC FIBER; ELECTRON MICROSCOPY; GELEOPHYSIC DYSPLASIA; GENETIC ASSOCIATION; GLAUCOMA; HUMAN; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; MARFAN SYNDROME; MICROFIBRIL DEFECT; NONHUMAN; OPEN ANGLE GLAUCOMA; OPTIC NERVE LESION; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN LOCALIZATION; PSEUDOEXFOLIATION; REVIEW; SIGNAL TRANSDUCTION; WEILL MARCHESANI SYNDROME; ANIMAL; DISEASE MODEL; DOG; EXTRACELLULAR MATRIX; FIBER; GENETICS; INTRAOCULAR PRESSURE; METABOLISM; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; EXTRACELLULAR MATRIX; GLAUCOMA; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MICROFIBRILS; MUTATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84898719215     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0184     Document Type: Review

References (121)

1. Kuchtey, J., Olson, L.M., Rinkoski, T., et al. Mapping of the disease locus and identification of ADAMTS10 as a candidate gene in a canine model of primary open angle glaucoma. PLoS Genet. 7:e1001306, 2011.
2. Thorleifsson, G., Magnusson, K.P., Sulem, P., et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 317:1397-1400, 2007.
3. Narooie-Nejad, M., Paylakhi, S.H., Shojaee, S., et al. Loss of function mutations in the gene encoding latent transforming growth factor beta binding protein 2, LTBP2, cause primary congenital glaucoma. Hum. Mol. Genet. 18:3969-3977, 2009.
4. Ali, M., McKibbin, M., Booth, A., et al. Null mutations in LTBP2 cause primary congenital glaucoma. Am. J. Hum. Genet. 84:664-671, 2009.
5. Izquierdo, N.J., Traboulsi, E.I., Enger, C., and Maumenee, I.H. Glaucoma in the Marfan syndrome. Trans. Am. Ophthalmol. Soc. 90:111-117; discussion 118-122, 1992.
6. Faivre, L., Collod-Beroud, G., Loeys, B.L., et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am. J. Hum. Genet. 81:454-466, 2007.
7. Kielty, C.M., Sherratt, M.J., Marson, A., and Baldock, C. Fibrillin microfibrils. Adv. Protein Chem. 70:405-436, 2005.
8. Ramirez, F., and Rifkin, D.B. Extracellular microfibrils: contextual platforms for TGFbeta and BMP signaling. Curr. Opin. Cell Biol. 21:616-622, 2009.
9. Ramirez, F., and Sakai, L.Y. Biogenesis and function of fibrillin assemblies. Cell Tissue Res. 339:71-82, 2010.
10. Jensen, S.A., Robertson, I.B., and Handford, P.A. Dissecting the fibrillin microfibril: structural insights into organization and function. Structure. 20:215-225, 2012.
11. Horiguchi, M., Ota, M., and Rifkin, D.B. Matrix control of transforming growth factor-beta function. J. Biochem. 152:321-329, 2012.
12. Jakus, M.A. Studies on the cornea. I. The fine structure of the rat cornea. Am. J. Ophthalmol. 38:40-53, 1954.
13. Karrer, H.E. The fine structure of connective tissue in the tunica propria of bronchioles. J. Ultrastruct. Res. 2:96-121, 1958.
14. Low, F.N. Microfibrils: fine filamentous components of the tissue space. Anat. Rec. 142:131-137, 1962.
15. Ross, R., and Bornstein, P. The elastic fiber. I. The separation and partial characterization of its macromolecular components. J. Cell Biol. 40:366-381, 1969.
16. Yanagisawa, H., and Davis, E.C. Unraveling the mechanism of elastic fiber assembly: the roles of short fibulins. Int. J. Biochem. Cell. Biol. 42:1084-1093, 2010.
17. Sakai, L.Y., Keene, D.R., and Engvall, E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J. Cell Biol. 103:2499-2509, 1986.
18. Robertson, I., Jensen, S., and Handford, P. TB domain proteins: evolutionary insights into the multifaceted roles of fibrillins and LTBPs. Biochem. J. 433:263-276, 2011.
19. Piha-Gossack, A., Sossin, W., and Reinhardt, D.P. The evolution of extracellular fibrillins and their functional domains. PLoS One 7:e33560, 2012.
20. Carta, L., Pereira, L., Arteaga-Solis, E., et al. Fibrillins 1 and 2 perform partially overlapping functions during aortic development. J. Biol. Chem. 281:8016-8023, 2006.
21. Shi, Y., Tu, Y., De Maria, A., Mecham, R.P., and Bassnett, S. Development, composition, and structural arrangements of the ciliary zonule of the mouse. Invest. Ophthalmol. Vis. Sci. 54:2504-2515, 2013.
22. Chaudhry, S.S., Cain, S.A., Morgan, A., Dallas, S.L., Shuttleworth, C.A., and Kielty, C.M. Fibrillin-1 regulates the bioavailability of TGFbeta1. J. Cell Biol. 176:355-367, 2007.
23. Massam-Wu, T., Chiu, M., Choudhury, R., et al. Assembly of fibrillin microfibrils governs extracellular deposition of latent TGF beta. J. Cell Sci. 123:3006-3018, 2010.
24. Hirani, R., Hanssen, E., and Gibson, M.A. LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar protein. Matrix Biol. 26:213-223, 2007.
25. Todorovic, V., and Rifkin, D.B. LTBPs, more than just an escort service. J. Cell Biochem. 113:410-418, 2012.
26. Sweetwyne, M.T., and Murphy-Ullrich, J.E. Thrombospondin1 in tissue repair and fibrosis: TGF-beta-dependent and independent mechanisms. Matrix Biol. 31:178-186, 2012.
27. Worthington, J.J., Klementowicz, J.E., and Travis, M.A. TGFbeta: a sleeping giant awoken by integrins. Trends Biochem. Sci. 36:47-54, 2011.
28. Yang, Z., Mu, Z., Dabovic, B., et al. Absence of integrinmediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J. Cell Biol. 176:787-793, 2007.
29. Matt, P., Schoenhoff, F., Habashi, J., et al. Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 120:526-532, 2009.
30. Neptune, E.R., Frischmeyer, P.A., Arking, D.E., et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33:407-411, 2003.
31. Ng, C.M., Cheng, A., Myers, L.A., et al. TGF-betadependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J. Clin. Invest. 114: 1586-1592, 2004.
32. Kim, K.L., Yang, J.H., Song, S.H., et al. Positive correlation between the dysregulation of transforming growth factor-beta1 and aneurysmal pathological changes in patients with Marfan syndrome. Circ. J. 77:952-958, 2013.
33. Sengle, G., Tsutsui, K., Keene, D.R., et al. Microenvironmental regulation by fibrillin-1. PLoS Genet. 8:e1002425, 2012.
34. Le Goff, C., Mahaut, C., Wang, L.W., et al. Mutations in the TGFbeta binding-protein-like domain 5 of FBN1 are responsible for acromicric and geleophysic dysplasias. Am. J. Hum. Genet. 89:7-14, 2011.
35. Le Goff, C., Morice-Picard, F., Dagoneau, N., et al. ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-beta bioavailability regulation. Nat. Genet. 40:1119-1123, 2008.
36. Loeys, B.L., Gerber, E.E., Riegert-Johnson, D., et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci. Transl. Med. 2:23ra20, 2010.
37. Callewaert, B., Su, C.T., Van Damme, T., et al. Comprehensive clinical and molecular analysis of 12 families with type 1 recessive cutis laxa. Hum. Mutat. 34:111-121, 2012.
38. Renard, M., Holm, T., Veith, R., et al. Altered TGFbeta signaling and cardiovascular manifestations in patients with autosomal recessive cutis laxa type I caused by fibulin-4 deficiency. Eur. J. Hum. Genet. 18:895-901, 2010.
39. Kinsey, R., Williamson, M.R., Chaudhry, S., et al. Fibrillin-1 microfibril deposition is dependent on fibronectin assembly. J. Cell Sci. 121:2696-2704, 2008.
40. Sabatier, L., Chen, D., Fagotto-Kaufmann, C., et al. Fibrillin assembly requires fibronectin. Mol. Biol. Cell 20:846-858, 2009.
41. Abraham, P.A., Perejda, A.J., Carnes, W.H., and Uitto, J. Marfan syndrome. Demonstration of abnormal elastin in aorta. J. Clin. Invest. 70:1245-1252, 1982.
42. Judge, D.P., Biery, N.J., Keene, D.R., et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J. Clin. Invest. 114:172-181, 2004.
43. Mariko, B., Pezet, M., Escoubet, B., et al. Fibrillin-1 genetic deficiency leads to pathological ageing of arteries in mice. J. Pathol. 224:33-44, 2011.
44. Ashton, N., Brini, A., and Smith, R. Anatomical studies of the trabecular meshwork of the normal human eye. Br. J. Ophthalmol. 40:257-282, 1956.
45. Iwamoto, T. Light and electron microscopy of the presumed elastic components of the trabeculae and scleral spur of the human eye. Invest. Ophthalmol. 3:144-156, 1964.
46. Rohen, J.W., Futa, R., and Lutjen-Drecoll, E. The fine structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest. Ophthalmol. Vis. Sci. 21:574-585, 1981.
47. Ueda, J., and Yue, B.Y. Distribution of myocilin and extracellular matrix components in the corneoscleral meshwork of human eyes. Invest. Ophthalmol. Vis. Sci. 44:4772-4779, 2003.
48. Gong, H.Y., Trinkaus-Randall, V., and Freddo, T.F. Ultrastructural immunocytochemical localization of elastin in normal human trabecular meshwork. Curr. Eye Res. 8:1071-1082, 1989.
49. Lutjen-Drecoll, E., Futa, R., and Rohen, J.W. Ultrahistochemical studies on tangential sections of the trabecular meshwork in normal and glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 21:563-573, 1981.
50. Ueda, J., Wentz-Hunter, K., and Yue, B.Y. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest. Ophthalmol. Vis. Sci. 43:1068-1076, 2002.
51. Hann, C.R., and Fautsch, M.P. The elastin fiber system between and adjacent to collector channels in the human juxtacanalicular tissue. Invest. Ophthalmol. Vis. Sci. 52:45-50, 2011.
52. Tektas, O.Y., and Lutjen-Drecoll, E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp. Eye Res. 88:769-775, 2009.
53. Wagenseil, J.E., and Mecham, R.P. Vascular extracellular matrix and arterial mechanics. Physiol. Rev. 89:957-989, 2009.
54. Umihira, J., Nagata, S., Nohara, M., Hanai, T., Usuda, N., and Segawa, K. Localization of elastin in the normal and glaucomatous human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 35:486-494, 1994.
55. Wheatley, H.M., Traboulsi, E.I., Flowers, B.E., et al. Immunohistochemical localization of fibrillin in human ocular tissues. Relevance to the Marfan syndrome. Arch. Ophthalmol. 113:103-109, 1995.
56. Schlotzer-Schrehardt, U., von der Mark, K., Sakai, L.Y., and Naumann, G.O. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 38:970-984, 1997.
57. Rohen, J.W., and Witmer, R. Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. 183:251-266, 1972.
58. Lutjen-Drecoll, E., Shimizu, T., Rohrbach, M., and Rohen, J.W. Quantitative analysis of 'plaque material' in the inner-and outer wall of Schlemm's canal in normal-and glaucomatous eyes. Exp. Eye Res. 42:443-455, 1986.
59. Rohen, J.W., Lutjen-Drecoll, E., Flugel, C., Meyer, M., and Grierson, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye. Res. 56:683-692, 1993.
60. Chung, A.W., Au Yeung, K., Sandor, G.G., Judge, D.P., Dietz, H.C., and van Breemen, C. Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and-9 in the thoracic aortic aneurysm in Marfan syndrome. Circ. Res. 101:512-522, 2007.
61. Johnstone, M.A. The aqueous outflow system as a mechanical pump: evidence from examination of tissue and aqueous movement in human and non-human primates. J. Glaucoma 13:421-438, 2004.
62. Johnstone, M., Martin, E., and Jamil, A. Pulsatile flow into the aqueous veins: manifestations in normal and glaucomatous eyes. Exp. Eye Res. 92:318-327, 2011.
63. Li, P., Reif, R., Zhi, Z., et al. Phase-sensitive optical coherence tomography characterization of pulse-induced trabecular meshwork displacement in ex vivo nonhuman primate eyes. J. Biomed. Opt. 17:076026, 2012.
64. Jeremy, R.W., Huang, H., Hwa, J., McCarron, H., Hughes, C.F., and Richards, J.G. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am. J. Cardiol. 74:369-373, 1994.
65. Gibson, G. Rare and common variants: twenty arguments. Nat. Rev. Genet. 13:135-145, 2012.
66. Liu, X., Zhao, Y., Gao, J., et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat. Genet. 36:178-182, 2004.
67. Kim, S., and Kim, Y. Variations in LOXL1 associated with exfoliation glaucoma do not affect amine oxidase activity. Mol. Vis. 18:265-270, 2012.
68. Jelodari-Mamaghani, S., Haji-Seyed-Javadi, R., Suri, F., et al. Contribution of the latent transforming growth factor-beta binding protein 2 gene to etiology of primary open angle glaucoma and pseudoexfoliation syndrome. Mol. Vis. 19:333-347, 2013.
69. Kuehn, M.H., McLellan, G.J., Pfleging, A., Snella, E.M., and Ellinwood, N.M. Spontaneous mutations In LTBP2 are associated with congenital glaucoma in cats. Invest. Ophthalmol. Vis. Sci. 52:2424, 2011.
70. Hirai, M., Horiguchi, M., Ohbayashi, T., Kita, T., Chien, K.R., and Nakamura, T. Latent TGF-beta-binding protein 2 binds to DANCE/fibulin-5 and regulates elastic fiber assembly. EMBO J. 26:3283-3295, 2007.
71. Kuchtey, J., Kunkel, J., Esson, D., et al. Screening ADAMTS10 in dog populations supports Gly661Arg as the glaucoma-causing variant in beagles. Invest. Ophthalmol. Vis. Sci. 54:1881-1886, 2013.
72. Somerville, R.P., Jungers, K.A., and Apte, S.S. Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation. J. Biol. Chem. 279:51208-51217, 2004.
73. Kutz, W.E., Wang, L.W., Bader, H.L., et al. ADAMTS10 protein interacts with fibrillin-1 and promotes its deposition in extracellular matrix of cultured fibroblasts. J. Biol. Chem. 286:17156-17167, 2011.
74. Dagoneau, N., Benoist-Lasselin, C., Huber, C., et al. ADAMTS10 mutations in autosomal recessive Weill-Marchesani syndrome. Am. J. Hum. Genet. 75:801-806, 2004.
75. Faivre, L., Gorlin, R.J., Wirtz, M.K., et al. In frame fibrillin-1 gene deletion in autosomal dominant Weill-Marchesani syndrome. J. Med. Genet. 40:34-36, 2003.
76. Faivre, L., Dollfus, H., Lyonnet, S., et al. Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome. Am. J. Med. Genet. A. 123A:204-207, 2003.
77. Hollister, D.W., Godfrey, M., Sakai, L.Y., and Pyeritz, R.E. Immunohistologic abnormalities of the microfibrillarfiber system in the Marfan syndrome. N. Engl. J. Med. 323:152-159, 1990.
78. Gelatt, K.N., Peiffer, R.L., Jr., Gwin, R.M., Gum, G.G., and Williams, L.W. Clinical manifestations of inherited glaucoma in the beagle. Invest. Ophthalmol. Vis. Sci. 16:1135-1142, 1977.
79. Heur, M., Costin, B., Crowe, S., et al. The value of keratometry and central corneal thickness measurements in the clinical diagnosis of Marfan syndrome. Am. J. Ophthalmol. 145:997-1001, 2008.
80. Sultan, G., Baudouin, C., Auzerie, O., De Saint Jean, M., Goldschild, M., and Pisella, P.J. Cornea in Marfan disease: orbscan and in vivo confocal microscopy analysis. Invest. Ophthalmol. Vis. Sci. 43:1757-1764, 2002.
81. Gordon, M.O., Beiser, J.A., Brandt, J.D., et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:714-720; discussion 829-730, 2002.
82. Gelaw, Y., Kollmann, M., Irungu, N.M., and Ilako, D.R. The influence of central corneal thickness on intraocular pressure measured by goldmann applanation tonometry among selected Ethiopian communities. J. Glaucoma. 19:514-518, 2010.
83. Park, S.J., Ang, G.S., Nicholas, S., and Wells, A.P. The effect of thin, thick, and normal corneas on Goldmann intraocular pressure measurements and correction formulae in individual eyes. Ophthalmology. 119:443-449, 2011.
84. Tripathi, R.C., Li, J., Chan, W.F., and Tripathi, B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 59:723-727, 1994.
85. Inatani, M., Tanihara, H., Katsuta, H., Honjo, M., Kido, N., and Honda, Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 239:109-113, 2001.
86. Ochiai, Y., and Ochiai, H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 46:249-253, 2002.
87. Picht, G., Welge-Luessen, U., Grehn, F., and Lutjen-Drecoll, E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207, 2001.
88. Schlotzer-Schrehardt, U., Zenkel, M., Kuchle, M., Sakai, L.Y., and Naumann, G.O. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp. Eye Res. 73:765-780, 2001.
89. Ozcan, A.A., Ozdemir, N., and Canataroglu, A. The aqueous levels of TGF-beta2 in patients with glaucoma. Int. Ophthalmol. 25:19-22, 2004.
90. Yamamoto, N., Itonaga, K., Marunouchi, T., and Majima, K. Concentration of transforming growth factor beta2 in aqueous humor. Ophthalmic Res. 37:29-33, 2005.
91. Min, S.H., Lee, T.I., Chung, Y.S., and Kim, H.K. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J. Ophthalmol. 20:162-165, 2006.
92. Fuchshofer, R., and Tamm, E.R. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res. 347:279-290, 2012.
93. Gottanka, J., Chan, D., Eichhorn, M., Lutjen-Drecoll, E., and Ethier, C.R. Effects of TGF-beta2 in perfused human eyes. Invest. Ophthalmol. Vis. Sci. 45:153-158, 2004.
94. Fleenor, D.L., Shepard, A.R., Hellberg, P.E., Jacobson, N., Pang, I.H., and Clark, A.F. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 47:226-234, 2006.
95. Robertson, J.V., Golesic, E., Gauldie, J., and West-Mays, J.A. Ocular gene transfer of active TGF-beta induces changes in anterior segment morphology and elevated IOP in rats. Invest. Ophthalmol. Vis. Sci. 51:308-318, 2010.
96. Shepard, A.R., Millar, J.C., Pang, I.H., Jacobson, N., Wang, W.H., and Clark, A.F. Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest. Ophthalmol. Vis. Sci. 51:2067-2076, 2010.
97. Robertson, J.V., Siwakoti, A., and West-Mays, J.A. Altered expression of transforming growth factor beta 1 and matrix metalloproteinase-9 results in elevated intraocular pressure in mice. Mol. Vis. 19:684-695, 2013.
98. Johnson, M. 'What controls aqueous humour outflow resistance?'. Exp. Eye Res. 82:545-557, 2006.
99. Acott, T.S., and Kelley, M.J. Extracellular matrix in the trabecular meshwork. Exp. Eye Res. 86:543-561, 2008.
100. Habashi, J.P., Judge, D.P., Holm, T.M., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 312:117-121, 2006.
101. Cohn, R.D., van Erp, C., Habashi, J.P., et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13:204-210, 2007.
102. Le Goff, C., and Cormier-Daire, V. From tall to short: the role of TGFbeta signaling in growth and its disorders. Am. J. Med. Genet. C Semin. Med. Genet. 160C:145-153, 2012.
103. Ljubimov, A.V., Saghizadeh, M., Spirin, K.S., Mecham, R.P., Sakai, L.Y., and Kenney, M.C. Increased expression of fibrillin-1 in human corneas with bullous keratopathy. Cornea. 17:309-314, 1998.
104. Lacro, R.V., Dietz, H.C., Wruck, L.M., et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am. Heart J. 154:624-631, 2007.
105. Nistala, H., Lee-Arteaga, S., Carta, L., et al. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum. Mol. Genet. 19:4790-4798, 2010.
106. Habashi, J.P., Doyle, J.J., Holm, T.M., et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science. 332:361-365, 2011.
107. Mavromoustakos, T., Agelis, G., and Durdagi, S. AT1 antagonists: a patent review (2008-2012). Expert Opin. Ther. Pat. 23:1483-1494, 2013.
108. Lavoie, P., Robitaille, G., Agharazii, M., Ledbetter, S., Lebel, M., and Lariviere, R. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J. Hypertens. 23:1895-1903, 2005.
109. Lim, D.S., Lutucuta, S., Bachireddy, P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 103:789-791, 2001.
110. Lanz, T.V., Ding, Z., Ho, P.P., et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 120:2782-2794, 2010.
111. Radonic, T., de Witte, P., Baars, M.J., Zwinderman, A.H., Mulder, B.J., and Groenink, M. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials. 11:3, 2010.
112. Vaajanen, A., Luhtala, S., Oksala, O., and Vapaatalo, H. Does the renin-angiotensin system also regulate intraocular pressure? Ann. Med. 40:418-427, 2008.
113. Shah, G.B., Sharma, S., Mehta, A.A., and Goyal, R.K. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma. J. Cardiovasc. Pharmacol. 36:169-175, 2000.
114. Inoue, T., Yokoyoma, T., Mori, Y., et al. The effect of topical CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure and aqueous humor dynamics in rabbits. Curr. Eye Res. 23:133-138, 2001.
115. Wang, R.F., Podos, S.M., Mittag, T.W., and Yokoyoma, T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp. Eye Res. 80:629-632, 2005.
116. Costagliola, C., Verolino, M., De Rosa, M.L., Iaccarino, G., Ciancaglini, M., and Mastropasqua, L. Effect of oral losartan potassium administration on intraocular pressure in normotensive and glaucomatous human subjects. Exp. Eye Res. 71:167-171, 2000.
117. Chen, J., Runyan, S.A., and Robinson, M.R. Novel ocular antihypertensive compounds in clinical trials. Clin. Ophthalmol. 5:667-677, 2011.
118. Holm, T.M., Habashi, J.P., Doyle, J.J., et al. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 332:358-361, 2011.
119. Santos, R.A., Ferreira, A.J., and Simoes, E.S.A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp. Physiol. 93:519-527, 2008.
120. Silveira, K.D., Barroso, L.C., Vieira, A.T., et al. Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS One 8:e66082, 2013.
121. Foureaux, G., Nogueira, J.C., Nogueira, B.S., et al. Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2. Invest. Ophthalmol. Vis. Sci. 54:4296-4306, 2013.